Why Neuronetics is back on investor radars Neuronetics (STIM) is drawing fresh attention after reporting preliminary fourth quarter 2025 revenue of US$41.8 million and generating positive operating ...

Neuronetics Inc. STIM shares soared 41.08% to $2.06 in after-hours trading on Tuesday following preliminary fourth-quarter ...

MALVERN, Pa. and TORONTO, Oct. 4, 2024 /PRNewswire/ - Neuronetics, Inc. (NASDAQ: STIM) ("Neuronetics") and Greenbrook TMS Inc. (OTCMKTS: GBNHF) ("Greenbrook") today ...

As of Wednesday, February 11, Neuronetics, Inc.’s STIM share price has surged by 21.58%, which has investors questioning if ...

All values provided represent preliminary unaudited results Fourth quarter 2025 revenue of $41.8 million, representing 86% year-over-year growth ...

Neuronetics, Inc., a medical technology company focused on mental health, has announced key updates regarding its NeuroStar therapy. The company will be a Silver Sponsor at the 13th Annual Clinical ...

Neuronetics, Inc. (NASDAQ:STIM) shareholders should be happy to see the share price up 28% in the last week. But will that heal all the wounds inflicted over 5 years of declines? Unlikely. Five years ...

Neuronetics is currently facing challenges from increased competition and a difficult macro environment, which is impacting growth and profitability. While market conditions appear to have stabilized ...

Neuronetics' share price dropped after reporting soft Q1 2024 results, with weak system sales undermining strong treatment demand. Neuronetics' losses remain relatively large, and the company's ...

MALVERN, Pa., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve ...

MALVERN, Pa., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Neuronetics, which has 203 ...